ConductScience.org, home

Paper16192597

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

D'Adamo DR and 8 others. J Clin Oncol, 2005. Cited by 202 papers, by iCite.

Cite this record

ConductScience Library. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. Papers, record 16192597. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16192597

Download JSON
Disease
soft tissue sarcoma233 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.
PubMed
Journal
J Clin Oncol
PubMed
Year
2005
PubMed
Publication types
Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
202
iCite
Relative citation ratio, by iCite
4.52
iCite
Revised in PubMed
2015-11-19
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1D'Adamo DRDavid R
2Anderson SESibyl E
3Albritton KKaren
4Yamada JJennifer
5Riedel EElyn
6Scheu KKelly
7Schwartz GKGary K
8Chen HHelen
9Maki RGRobert G

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
SarcomaMajor topic
Adult
Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab
Doxorubicin
Female
Humans
Infusions, Intravenous
Injections, Intravenous
Male
Middle Aged
Neoplasm Metastasis
Treatment Outcome

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
N01-CM17105NCI NIH HHSUnited StatesPubMedPubMed
P01 CA47179NCI NIH HHSUnited StatesP01CA047179PubMed and NIHNIH RePORTER

Download CSV of grants

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00052390Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue SarcomaResultsClinicalTrials.gov
NCT00908219A Study of Bevacizumab to Prevent Malignant AscitesBackgroundClinicalTrials.gov
NCT05366062ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and PembrolizumabBackgroundClinicalTrials.gov

Download CSV of trials

Cited by72

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 202 citations.

PMIDTitleJournalYearIn PapersSource
41132824Efficacy and safety of vascular-targeting agents in advanced soft tissue sarcoma: a systematic review and network meta-analysis.Ther Adv Med Oncol2025https://conductscience.org/library/papers/41132824PubMed
40481994Cancer therapy-induced cardiotoxicity: mechanisms and mitigations.Heart Fail Rev2025https://conductscience.org/library/papers/40481994PubMed
40370992Simultaneous, Seconds-Resolved Doxorubicin Measurements in the Blood and Subcutaneous Interstitial Fluid Identify Quantitative Pharmacokinetic Relationships between the Two.ACS Pharmacol Transl Sci2025https://conductscience.org/library/papers/40370992PubMed
37568826Maintenance Chemotherapy for Patients with Rhabdomyosarcoma.Cancers (Basel)2023https://conductscience.org/library/papers/37568826PubMed
37081717Evaluation of the efficacy of systemic therapy for advanced uterine leiomyosarcoma: A systematic review, meta-analysis, and meta-regression analysis.Cancer Med2023https://conductscience.org/library/papers/37081717PubMed
36497280Knockdown of NCOR2 Inhibits Cell Proliferation via BDNF/TrkB/ERK in NF1-Derived MPNSTs.Cancers (Basel)2022https://conductscience.org/library/papers/36497280PubMed
36267741Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial.Ann Transl Med2022https://conductscience.org/library/papers/36267741PubMed
34094927Primary Intracranial Leiomyosarcoma Secondary to Glioblastoma: Case Report and Literature Review.Front Oncol2021https://conductscience.org/library/papers/34094927PubMed
33842348VEGFR Inhibitors for Uterine Metastatic Perivascular Epithelioid Tumors (PEComa) Resistant to mTOR Inhibitors. A Case Report and Review of Literature.Front Oncol2021https://conductscience.org/library/papers/33842348PubMed
33574700Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas.Cancer Manag Res2021https://conductscience.org/library/papers/33574700PubMed
33330082Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials.Front Oncol2020https://conductscience.org/library/papers/33330082PubMed
32974853Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.Invest New Drugs2021https://conductscience.org/library/papers/32974853PubMed
32905214Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature.Mol Clin Oncol2020https://conductscience.org/library/papers/32905214PubMed
32824667Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab.J Clin Med2020https://conductscience.org/library/papers/32824667PubMed
32127798Integrative Clustering Reveals a Novel Subtype of Soft Tissue Sarcoma With Poor Prognosis.Front Genet2020https://conductscience.org/library/papers/32127798PubMed
32039918Inactivation of endothelial ZEB1 impedes tumor progression and sensitizes tumors to conventional therapies.J Clin Invest2020https://conductscience.org/library/papers/32039918PubMed
30126857A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.Oncologist2019https://conductscience.org/library/papers/30126857PubMed
29890998Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.J Transl Med2018https://conductscience.org/library/papers/29890998PubMed
29527631Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.Invest New Drugs2018https://conductscience.org/library/papers/29527631PubMed
29462961A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas.Cancers (Basel)2018https://conductscience.org/library/papers/29462961PubMed

See all 72 cited byDownload CSV of cited by

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
BEVACIZUMABCHEMBL1201583Results1https://conductscience.org/library/drugs/CHEMBL1201583ChEMBL
DOXORUBICINCHEMBL53463Results1https://conductscience.org/library/drugs/CHEMBL53463ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/16192597

GET https://conductscience.org/api/papers/v1/16192597/cited_by?page=2